Memantine Hydrochloride
Product Images NDC 50090-4877

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-4877). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904877)

Memantine Hydrochloride 10 mg face tablet container label from A-S Medication Solutions. The label includes dosage strength, quantity of 90 tablets, storage instructions, lot number, and package barcode. It indicates the product is for oral use and provides manufacturer information from Lannett Company, Inc.*

FDA Label Image

Memantine-hcl-molec-struc (Memantine Hydrochloride Tablets 1)

FDA Label Image

Fig1 (Memantine Hydrochloride Tablets 2)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 28 weeks of treatment comparing Memantine and placebo. The graph shows clinical improvement and clinical decline reference lines, with Memantine and placebo trends plotted over time along with error bars representing SEM.*

FDA Label Image

Fig2 (Memantine Hydrochloride Tablets 3)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline for Memantine Hydrochloride compared to placebo. The x-axis represents ADCS-ADL change from baseline, and the y-axis indicates cumulative percentage of patients. Two curves are plotted: one for placebo and one for memantine, allowing comparison of patient response distributions.*

FDA Label Image

Fig3 (Memantine Hydrochloride Tablets 4)

A line graph comparing mean change in SIB scores from baseline over 28 weeks of treatment between Memantine and placebo groups. The y-axis shows mean change with SEM, and the x-axis shows weeks of treatment. Memantine maintains near baseline scores while placebo shows a decline. Dashed lines mark clinical improvement and decline.*

FDA Label Image

Fig4 (Memantine Hydrochloride Tablets 5)

A cumulative percentage of patients graph comparing Placebo and Memantine treatment groups, showing SIB (Severe Impairment Battery) change from baseline on the X-axis and cumulative percentage of patients on the Y-axis. Memantine data points are marked with circles, and Placebo with squares, illustrating greater cumulative improvement with Memantine.*

FDA Label Image

Fig5 (Memantine Hydrochloride Tablets 6)

A line graph showing mean (± SEM) change from baseline in ADCS-ADL scores over 24 weeks of treatment comparing Placebo/Donepezil and Memantine/Donepezil groups. The graph depicts clinical improvement and decline thresholds, with Memantine/Donepezil showing less decline than Placebo/Donepezil across the treatment period.*

FDA Label Image

Fig6 (Memantine Hydrochloride Tablets 7)

A cumulative percentage of patients chart showing ADCS-ADL change from baseline with two plotted lines comparing Placebo/Donepezil and Memantine/Donepezil treatment groups. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients, with data points indicated by squares and circles for each group respectively.*

FDA Label Image

Fig7 (Memantine Hydrochloride Tablets 8)

A line graph showing the mean (± SEM) change from baseline in SIB score over 24 weeks of treatment, comparing Placebo/Donepezil and Memantine/Donepezil. The x-axis represents weeks of treatment, and the y-axis represents change in SIB score with labels for clinical improvement and decline. Data points with error bars illustrate trends for both groups throughout the study period.*

FDA Label Image

Fig8 (Memantine Hydrochloride Tablets 9)

A cumulative percentage of patients versus SIB change from baseline line graph comparing Placebo/Donepezil and Memantine/Donepezil. The x-axis represents SIB change from baseline ranging from 20 to -30, while the y-axis shows cumulative percentage from 0 to 100%. The Memantine/Donepezil group shows a higher cumulative percentage of patients achieving larger negative SIB changes compared to the Placebo/Donepezil group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.